Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines
Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.
How this was made

The 30-second read
Why it matters
The call reaffirmed guidance and disclosed a slight improvement in gross-to-net, offering limited new material for price action.
Market read
Earnings call provides modest new data; unlikely to trigger large price moves.
What to watch
Potential future label expansion for IBSRELA into CIC could drive longer-term upside not reflected in the call.
Background
Ardelyx discussed IBSRELA performance, pharmacy network dynamics, and gross-to-net metrics during its Q3 2026 earnings call.
Ticker impact
Earnings call disclosed reaffirmed guidance and Q3 gross-to-net of 31.7%, a new data point for Ardelyx.
likely modest upside as investors price in stable outlook
No major guidance change or surprise; the new gross-to-net figure is incremental and does not imply a sharp move.
Market effects
Provides a modest data point for the biotech/IBS therapeutic sector but no sector-wide catalyst.
Limited to US biotech investors; no broader regional effect.
Low global relevance; primarily impacts Ardelyx shareholders.
Counterpoint
If investors expect a guidance downgrade, the reaffirmation could be seen as a positive surprise.
Key entities
- CompanyArdelyx Inc
Biopharma focused on kidney disease therapies.

